AbbVie Reports Third-Quarter 2015 Financial Results - Reports Third-Quarter Adjusted EPS of $1.13, Up Nearly 27 Percent and Exceeding Previous Guidance Range of $1.04 to $1.06; Reports GAAP EPS of $0.74- Delivers Third-Quarter Revenue of $5.944 Billion, an Increase of 26.2 Percent Over Third-Quarter 2014 on an Operational Basis (Excluding 7.8 Percent Unfavorable Exchange); Reported Sales Increased 18.4 Percent- Revenue Growth Reflects 19.6 Percent Global Operational Sales Growth from HUMIRA (Excluding 7.5 Percent Unfavorable Exchange); Reported Global HUMIRA Sales Increased 12.1 Percent- Third-Quarter Global IMBRUVICA Net Revenue was $304 Million; U.S. Sales of IMBRUVICA were $267 Million; Third-Quarter Global VIEKIRA Sales were $469 Million- Achieves Adjusted Operating Margin Expansion to 44.9 Percent of Sales; Adjusted Gross Margin Improves to 83.3 Percent of Sales- Raises 2015 Adjusted EPS Guidance Range to $4.26 to $4.28; GAAP EPS Range of $3.16 to $3.18- Company Issues Long-Term Financial Objectives through 2020 and Issues Strong 2016 EPS Guidance (See Separate Release)

, Oct. 30, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced financial results for the third quarter ended September 30, 2015. "We are pleased with our outperformance in the third quarter and our progress year-to-date. We've driven strong commercial, operational and R&D execution, resulting in industry-leading top- and bottom-line performance," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "We are well-positioned to deliver robust EPS growth in 2015 and beyond, and we continue to make significant progress advancing our pipeline and other strategic actions that will help AbbVie achieve top-tier growth over the long term." Third-Quarter Results Worldwide...